Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers

Song, Mingming; Dong, Shuqi; An, Xiaofei; Zhang, Wenxiang; Shen, Ning; Li, Yanbo; Guo, Caixia; Liu, Chang; Li, Xiao; Chen, Siyu

doi:10.1016/j.jconrel.2022.03.060

Cited by 30 publications

(25 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, decorating NPs surfaces with erythrocytes, thrombocytes and leukocytes, help to reduce MP elimination (Brenner et al 2021 ). As it appears to be an ideal solution, a wide array of NPs were coated with cellular components like RBCs, platelets, exosomes and leukocytes (Song et al 2022 ). RBC-coating provided the increased circulatory half-life to the NPs by passive targeting.…”

Section: Blood Circulationmentioning

confidence: 99%

Nanomedicines: intervention in inflammatory pathways of cancer

Anwar

Naqvi

Shams³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

Inflammation is a complex defense process that maintains tissue homeostasis. However, this complex cascade, if lasts long, may contribute to pathogenesis of several diseases. Chronic inflammation has been exhaustively studied in the last few decades, for its contribution in development and progression of cancer. The intrinsic limitations of conventional anti-inflammatory and anti-cancer therapies triggered the development of nanomedicines for more effective and safer therapies. Targeting inflammation and tumor cells by nanoparticles, encapsulated with active therapeutic agents, offers a promising outcome with patient survival. Considerable technological success has been achieved in this field through exploitation of tumor microenvironment, and recognition of molecules overexpressed on endothelial cells or macrophages, through enhanced vascular permeability, or by rendering biomimetic approach to nanoparticles. This review focusses on the inflammatory pathways in progression of a tumor, and advancement in nanotechnologies targeting these pathways. We also aim to identify the gaps that hinder the successful clinical translation of nanotherapeutics with further clinical studies that will allow oncologist to precisely identify the patients who may be benefited from nanotherapy at time when promotion or progression of tumor initiates. It is postulated that the nanomedicines, in near future, will shift the paradigm of cancer treatment and improve patient survival. Graphical abstract

show abstract

Section: Blood Circulationmentioning

confidence: 99%

Nanomedicines: intervention in inflammatory pathways of cancer

Anwar

Naqvi

Shams³

et al. 2023

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated the usefulness of the RBCM in encapsulating drug-loaded polymeric NPs [ 38 ]. In the latest study, Song et al designed a novel polyethylene glycol (PEG)-FA NDDS (FRCS NP)-modified RBCM based on the refined “core-shell” structure of the RBCM [ 39 ]. The study found that FRCS NPs exhibited good biocompatibility and improved anti-melanoma efficacy in an acidic tumor microenvironment.…”

Section: Cutaneous Melanomamentioning

confidence: 99%

Advances in the Application of Nanomaterials to the Treatment of Melanoma

Wang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Melanoma can be divided into cutaneous melanoma, uveal melanoma, mucosal melanoma, etc. It is a very aggressive tumor that is prone to metastasis. Patients with metastatic melanoma have a poor prognosis and shorter survival. Although current melanoma treatments have been dramatically improved, there are still many problems such as systemic toxicity and the off-target effects of drugs. The use of nanoparticles may overcome some inadequacies of current melanoma treatments. In this review, we summarize the limitations of current therapies for cutaneous melanoma, uveal melanoma, and mucosal melanoma, as well as the adjunct role of nanoparticles in different treatment modalities. We suggest that nanomaterials may have an effective intervention in melanoma treatment in the future.

show abstract

“…In particular, the self-recognition protein CD47 on the erythrocyte membrane surface can inhibit erythrocyte phagocytosis by immune cells, which gives nanocarriers a superior half-life in systemic circulation. 35 CD44 is highly expressed in breast cancer cells and can selectively bind to hyaluronic acid (HA). 36–38 Thus, HA modification of the erythrocyte membrane can enhance the tumor-specific accumulation of nanodrugs.…”

Section: Introductionmentioning

confidence: 99%